EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Impact of Lactobacillus crispatus-containing oral and vaginal probiotics on vaginal health: a randomised double-blind placebo controlled clinical trial

R Mändar, G Sõerunurk, J Štšepetova, I Smidt, T Rööp, S Kõljalg, M Saare, K Ausmees, D D Le, M Jaagura, S Piiskop, H Tamm und 1 weitere

Beneficial Microbes · 14.04.2023 · 14 (2) · 143-152

DOI: 10.3920/bm2022.0091 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Beneficial Microbes, erschienen am 14.04.2023. Verfasst von R Mändar und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, 50411 Tartu, Estonia. Hauptthemen laut MEDLINE: Lactobacillus crispatus, Probiotics, Vaginosis, Bacterial, Candidiasis, Vulvovaginal. Die Arbeit wurde bisher 80-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Health of reproductive tract is tightly associated with balance of microbial communities in this area. Bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC) represent common disturbances of vaginal communities. Vaginal discharge due to BV or VVC is a very frequent reason for visiting gynaecologist. We aimed to evaluate the impact of the novel evidence-based probiotics on BV and VVC patients. The study group included 89 BV and 93 VVC patients (aged 18-50 years) who were recruited into randomised double-blind placebo-controlled two-arm parallel trial. The patients of each diagnosis group received oral or vaginal probiotic capsules, or placebo capsules during 3 months. A probiotic capsule contained two (DSM32717 and DSM32720, in case of BV) or three (DSM32720, DSM32718 and DSM32716, in case of VVC) Lactobacillus crispatus strains. Vaginal, intestinal and general health was monitored weekly by questionnaire. Blood analyses were done in the beginning and at the end of trial. Vaginal samples were collected monthly, microscopic and molecular analyses were performed. The study revealed that both oral and vaginal capsules reduced the signs and symptoms in BV patients. Remarkable improvement was noted in Nugent score, amount and smell of discharge, but also in itching/irritation. Consumption of vaginal probiotics significantly increased the lactobacilli counts in their vagina while mean proportion of some BV-related bacteria decreased. In VVC patients, both oral and vaginal capsules lowered the combined score of two most important symptoms, amount of discharge and itching/irritation. In conclusion, the novel formulations of evidence-based well-focused probiotic L. crispatus strains are effective against BV and VVC being suitable for both vaginal and oral administration. Clinical trial registration: ISRCTN34840624, BioMed Central

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lactobacillus crispatusProbioticsVaginosis, BacterialCandidiasis, VulvovaginalFemaleHumansVaginaDouble-Blind Method

Stichwörter der Autor:innen

Lactobacillus crispatusbacterial vaginosisprobioticvaginal healthvulvovaginal candidiasis

Autor:innen und Institutionen

  • Department of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, 50411 Tartu, Estonia.
  • Competence Center on Health Technologies, Teaduspargi tn 13, 50411 Tartu, Estonia.
  • MediTA Clinic, Teguri 37b, 51013 Tartu, Estonia.
  • Faculty of Public Health, University of Medicine and Pharmacy, Hue University, 06 Ngo Quyen, Hue 53000, Vietnam.
  • Institute of Genomics, University of Tartu, Riia 23b, 51010 Tartu, Estonia.
  • Chemi-Pharm AS, Tänassilma tee 11, Tänassilma, 76406 Harju maakond, Estonia.

Zitieren

APA

Mändar, R., Sõerunurk, G., Štšepetova, J., Smidt, I., Rööp, T., Kõljalg, S., Saare, M., Ausmees, K., Le, D. D., Jaagura, M., Piiskop, S., Tamm, H., & Salumets, A. (2023). Impact of Lactobacillus crispatus-containing oral and vaginal probiotics on vaginal health: a randomised double-blind placebo controlled clinical trial. Beneficial Microbes, 14(2), 143-152. https://doi.org/10.3920/bm2022.0091

Vancouver

Mändar R, Sõerunurk G, Štšepetova J, Smidt I, Rööp T, Kõljalg S, et al. Impact of Lactobacillus crispatus-containing oral and vaginal probiotics on vaginal health: a randomised double-blind placebo controlled clinical trial. Beneficial Microbes. 2023;14(2):143-152. doi:10.3920/bm2022.0091

BibTeX
@article{Mndar2023,
  author = {Mändar, R and Sõerunurk, G and Štšepetova, J and Smidt, I and Rööp, T and Kõljalg, S and Saare, M and Ausmees, K and Le, D D and Jaagura, M and Piiskop, S and Tamm, H and Salumets, A},
  title = {Impact of Lactobacillus crispatus-containing oral and vaginal probiotics on vaginal health: a randomised double-blind placebo controlled clinical trial},
  journal = {Beneficial Microbes},
  year = {2023},
  volume = {14},
  number = {2},
  pages = {143--152},
  doi = {10.3920/bm2022.0091}
}
Kostenlos starten →